George Cyriac

N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Robert R Luedtke, Peter Grundt, Michelle Taylor, 2009, Journal of medicinal chemistry.

Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.

A. Newman, P. Plenge, C. Loland, 2013, Journal of medicinal chemistry.

Emerging biomarkers for immune checkpoint inhibition in lung cancer.

L. Gandhi, George Cyriac, 2018, Seminars in cancer biology.

A Pictorial Essay of Immunotherapy: Complications that internists will see, whether they like it or not.

K. Gage, T. Rose, D. Jeong, 2019, The American journal of medicine.

Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.

J. Javitch, A. Newman, Yongfang Zhao, 2010, Journal of medicinal chemistry.

Emerging protein kinase inhibitors for non-small cell lung cancer

G. Giaccone, Stephen V. Liu, Deepa S. Subramaniam, 2013, Expert opinion on emerging drugs.

Invasive orbital aspergillosis in an apparently immunocompetent host without evidence sinusitis

George Cyriac, Princy N. Kumar, J. Primeggia, 2012 .